Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000460787 | SCV000552289 | benign | Tuberous sclerosis 1 | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001020253 | SCV001181708 | likely benign | Hereditary cancer-predisposing syndrome | 2021-07-28 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV001554985 | SCV001776330 | likely benign | not provided | 2020-06-15 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000460787 | SCV002039989 | likely benign | Tuberous sclerosis 1 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV004001894 | SCV004831296 | likely benign | Tuberous sclerosis syndrome | 2023-12-13 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003899930 | SCV004717722 | uncertain significance | TSC1-related disorder | 2023-11-10 | no assertion criteria provided | clinical testing | The TSC1 c.3419C>T variant is predicted to result in the amino acid substitution p.Pro1140Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.020% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-135771698-G-A). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |